Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.
Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.
Raymond L. Comenzo, MD, discusses his findings at the ASCO 2018 meeting.
James L. Gulley, MD, PhD, FACP, discusses his findings at ASCO 2018 meeting.
Paul Nghiem, MD, PhD, discusses his findings at the ASCO 2018 meeting.
Kyu Rhee, MD, MPP, discusses the latest updates at the ASCO 2018 meeting.
Previous studies demonstrated that FOLFIRINOX is more effective than gemcitabine as first-line treatment for patients with metastatic pancreatic cancer with good performance status.
Evidence suggests that neoadjuvant chemoradiotherapy may afford benefit, but this hypothesis requires further validation.
EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.
Please login or register first to view this content.
